Traceability Breaks at the Hand-Off By 0pcter

A company can know exactly what it shipped and still be unable to reconstruct where a product came from. Its supplier may also possess accurate records, as may the distributor, processor, and retailer. The failure can occur between them, where one organization's information must become another organization's evidence.

The U.S. Food and Drug Administration recently tested that problem across six food supply chains. Fifteen companies participated, including producers, processors, distributors, restaurants, and retailers, and were asked to provide required traceability information in an electronically sortable spreadsheet within 24 hours. Most companies met the time requirement. Yet several exercises still could not reconstruct the supply chain all the way to the original source.

The result exposes a problem that is easy to mistake for a database problem. Participants used invoices, purchase orders, bills of lading, warehouse-management systems, enterprise software, RFID, barcodes, and other technologies. Larger companies generally possessed more sophisticated systems, but FDA found that the technology itself was less important than whether trading partners had agreed beforehand on what information they would collect and how they would exchange it.

Where companies coordinated in advance, the difference was substantial. In at least two exercises, retailers or restaurants worked with suppliers to return information covering the entire supply chain within the initial 24-hour period. FDA estimated that the same reconstruction might otherwise have required 48 to 96 hours or longer through successive requests.

The weakness became clearer in the identifiers intended to hold the chain together. A Traceability Lot Code was available or inconsistently present in 80 percent of participant records, while information identifying where that code originated appeared in 73 percent. But only 40 percent properly recorded the lot code across every relevant tracking event, and only 27 percent completely recorded its source across those events.

Those numbers come from a small voluntary exercise and should not be generalized to the entire food industry. FDA explicitly warns that the fifteen participants were not representative of the broader market and that the exercises were simpler than an actual outbreak investigation. The findings therefore do not prove that American food traceability broadly fails at these rates. They demonstrate something narrower and more useful: individually available information does not automatically become interoperable evidence.

Consider what happened when the pieces separated. Some companies could provide a lot code but could not accurately identify where it had originally been assigned. Others could identify the source location but did not have the corresponding lot code. In another case, a company could not definitively determine its immediate previous supplier, so FDA had nowhere reliable to send the next request.

None of these failures requires the underlying record to have been falsified. The invoice can be authentic, the shipment record can be unchanged, and the warehouse database can accurately describe what that company saw. The chain can still break because the information required to connect one participant's event to the next participant's event was never captured consistently.

This is different from the familiar problem of information being difficult to find. A perfectly searchable warehouse record is still insufficient if the identifier necessary to connect it to the upstream processor is missing or means something different in another system. Findability asks whether the record can be located; interoperability asks whether independently maintained records can be made to describe the same chain of events.

Industry has spent years developing conventional tools for precisely this reason. GS1's traceability standards define Critical Tracking Events and Key Data Elements so companies can describe who, what, where, when, and why using a shared structure. Its EPCIS standard goes further by providing a common language for exchanging event information across organizations rather than requiring every company to operate the same database.

That distinction matters because standardization and centralization are not the same thing. Two companies do not need to store their information in one database to communicate successfully, but they do need enough agreement about identifiers, events, locations, and meanings for one system to interpret what the other sends. GS1 explicitly describes standardized vocabulary as critical to interoperability because it reduces differences in how companies express the same business event.

FDA encountered the opposite problem when individual buyers imposed different requirements on their suppliers. Some requirements went beyond the federal rule and demanded particular formats or scanning procedures, forcing suppliers to build custom solutions for different customer relationships. FDA concluded that greater harmonization between buyers and suppliers could reduce that burden.

This creates an important test for blockchain-based supply-chain claims. A blockchain can preserve a transaction, timestamp a commitment, establish ordering, and make subsequent alteration of committed information detectable. None of those properties tells two companies what a “shipping event” means, which identifier should follow a transformed product, or which fields must remain linked when goods cross organizational boundaries.

A blockchain can therefore preserve incompatible records perfectly. That does not make a public ledger useless. Once participants agree about what an event means and which information must accompany it, an independently verifiable history could potentially strengthen the evidentiary layer. A company could commit to an event record and later demonstrate that the record presented during an investigation matches what existed at an earlier time.

But that solves a later problem. It can help answer whether a previously created record changed; it cannot create the missing relationship between two records that were never compatible in the first place. Bitcoin cannot recover a lot identifier that nobody captured, determine which warehouse should have been recorded as the source, or force two companies to describe the same physical event consistently.

BSV's low transaction costs and capacity for data commitments could make frequent event commitments technically feasible. Feasibility, however, is not evidence of necessity. Existing GS1 identifiers, EPCIS event structures, databases, digital signatures, and conventional audit systems already address much of the operational traceability problem, and any Bitcoin architecture would still need those semantic agreements underneath it.

The FDA exercises therefore reveal something more fundamental than which traceability technology companies should buy. Successful reconstruction depends on the connections between records, not merely the existence of records themselves. A supply chain is not made traceable because every participant possesses data; it becomes traceable when an event recorded by one participant can be reliably connected to the event recorded by the next.

That principle extends well beyond food. Healthcare records, software supply chains, financial transactions, government systems, industrial maintenance histories, and future machine-to-machine commerce all cross organizational boundaries. As those systems become more automated, preserving records will matter, but agreeing on what those records describe may matter first.

The infrastructure problem therefore has at least two separate layers. Interoperability makes independently produced records intelligible to one another; verification makes claims about those records testable. Confusing the two encourages expensive technical solutions to problems that are actually failures of coordination.

Bitcoin may strengthen the second layer in circumstances where independent historical evidence genuinely matters. It cannot substitute for the first. The lesson from FDA's exercise is unusually simple: the weakest point in a traceability system may not be where information is stored. It may be the moment one organization's record has to become another organization's meaning.